Trial · NCT06899594
Psilocybin for Methamphetamine Addiction
NCT06899594, Early phase 1, Recruiting, Kevin Murnane
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Psilocybin for Methamphetamine Addiction. Trials, record NCT06899594. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06899594
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Psilocybin for Methamphetamine Addiction
- NCT number
- NCT06899594
- Status
- Recruiting
- Phases
- Early phase 1
- Enrollment
- 20 participants, estimated
- Lead sponsor
- Kevin Murnane
- Conditions
- Methamphetamine Use Disorder
- Interventions
- Psilocybin 25 mg
- First posted
- 2025-03-28
- Last updated
- 2025-10-07
Source ClinicalTrials.gov
Registered outcomes40
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Participant retention rate | Screening, Visit #1 | Description: Retention in the study will be assessed by measuring the percentage of study visits completed per participant. Measure: * Retention rate (percent of scheduled study visits completed by each participant). |
| Primary | Participant retention rate | Baseline Assessments, Visit #2 | Description: Retention in the study will be assessed by measuring the percentage of study visits completed per participant. Measure: * Retention rate (percent of scheduled study visits completed by each participant). |
| Primary | Participant retention rate | Preparatory Session #1, Visit #3 (on study day (-)14; 14 days prior to dosing) | Description: Retention in the study will be assessed by measuring the percentage of study visits completed per participant. Measure: * Retention rate (percent of scheduled study visits completed by each participant). |
| Primary | Participant retention rate | Preparatory Session #2, Visit #4 (on study day (-) 7; 7 days prior to dosing) | Description: Retention in the study will be assessed by measuring the percentage of study visits completed per participant. Measure: * Retention rate (percent of scheduled study visits completed by each participant). |
| Primary | Participant retention rate | Preparatory Session #3, Visit #5 (on study day (-)3; 3 days prior to dosing) | Description: Retention in the study will be assessed by measuring the percentage of study visits completed per participant. Measure: * Retention rate (percent of scheduled study visits completed by each participant). |
| Primary | Participant retention rate | Day of drug administration, Visit #6 (on study day 0) | Description: Retention in the study will be assessed by measuring the percentage of study visits completed per participant. Measure: * Retention rate (percent of scheduled study visits completed by each participant). |
| Primary | Participant retention rate | 1-Day post drug administration integration session, Visit #7 | Description: Retention in the study will be assessed by measuring the percentage of study visits completed per participant. Measure: * Retention rate (percent of scheduled study visits completed by each participant). |
| Primary | Participant retention rate | 7-Day post drug administration integration session, Visit #8 | Description: Retention in the study will be assessed by measuring the percentage of study visits completed per participant. Measure: * Retention rate (percent of scheduled study visits completed by each participant). |
| Primary | Participant retention rate | 30-days post drug administration follow-up (Follow-up #1), Visit #9 | Description: Retention in the study will be assessed by measuring the percentage of study visits completed per participant. Measure: * Retention rate (percent of scheduled study visits completed by each participant). |
| Primary | Participant retention rate | 60-days post drug administration follow-up (Follow-up #2), Visit #10 | Description: Retention in the study will be assessed by measuring the percentage of study visits completed per participant. Measure: * Retention rate (percent of scheduled study visits completed by each participant). |
1 to 10 of 40Source ClinicalTrials.gov
See all 40 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests4
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|---|---|
| Stroop Color-Word Test | Other outcome | ConductCognition |
| Symbol Coding | Other outcome | ConductCognition |
| Task Switching Test | Other outcome | ConductCognition |
| Trail Making Test B | Other outcome | ConductCognition |
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06899594
GET https://conductscience.org/api/trials/v1/NCT06899594/registered?page=2